Keywords: ares-serono, sales, growth, still, led, infertility, products
Ares-Serono Sales Growth Still Led By Infertility Products
Article | 27 January 1997
Switzerland-based Ares-Serono reported full-year 1996 sales up 18% at$682.3 million. For the fourth quarter, however, the company saw worldwide turnover grow 34.9% to $179.6 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
